Frequently Asked Questions About RGCC Cancer Monitoring Tests
Clearing up doubts about circulating tumour cell (CTC) monitoring
RGCC cancer monitoring tests (OncoTrace, Onco-D-clare, Onconomics Plus®, etc.) have become valuable supportive tools for many patients during post-surgical follow-up, active treatment, or long-term surveillance.
Below are answers to the questions most frequently asked by patients and families, explained in the most straightforward and evidence-based way.
What exactly is RGCC testing, and how does it differ from traditional tumour markers?
RGCC testing directly captures and analyses circulating tumour cells (CTCs) from the blood, providing information on cell count, activity, phenotype, and drug sensitivity.
Traditional tumour markers (e.g. CEA, CA19-9) are indirect indicators that can be influenced by inflammation or infection; RGCC targets the tumour cells themselves, offering earlier and more precise insight into disease dynamics.
When is RGCC monitoring most appropriate?
- Intermediate- to high-risk solid-tumour patients after surgery
- Patients completing adjuvant therapy and entering surveillance
- Those with fluctuating tumour markers but normal imaging
- Individuals with a history of metastasis hoping for earlier detection of recurrence
- Patients interested in understanding tumour sensitivity to drugs or natural compounds
Does one blood draw tell me if cancer has returned?
A single test provides a current snapshot; its true value lies in serial testing that creates a trend chart.
Stable or declining CTC counts generally indicate good disease control; a sudden rise can serve as an early alert for further evaluation.
Is the test safe and painful?
It requires only one tube of peripheral blood (approximately 20 ml), no different from a routine blood draw — no radiation, no invasive procedure, suitable for pregnant women and elderly patients.
How long until results are available, and how are they interpreted?
Blood samples are sent to the RGCC headquarters laboratory in Greece; reports are typically ready in 2–4 weeks.
The report includes CTC count trends, phenotype analysis, and drug sensitivity data. Your physician will review it with simple charts and plain-language explanation during a dedicated consultation.
Is it expensive, and is it worth it?
Costs vary by test type (OncoTrace, Onco-D-clare, Onconomics Plus®).
For many patients, the reassurance of earlier detection, avoidance of ineffective treatments, and reduced need for frequent imaging far outweigh the investment.
Summary
RGCC cancer monitoring is not about “predicting the future” —
it is about giving you clearer, earlier vision into your tumour’s behaviour.
It transforms follow-up from passive waiting into active, informed management,
turning each report into a source of confidence rather than concern.
If you have additional questions about RGCC testing — such as differences between tests, preparation, or sample reports —
please feel welcome to contact us.
Our team will conduct a comprehensive assessment and provide recommendations based on your individual circumstances, led by a specialist physician.
You deserve follow-up that feels clear, calm, and empowering every step of the way.
Disclaimer：
The information provided in this article is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, nor should it replace professional medical advice. Readers are encouraged to consult with a qualified healthcare provider or integrative oncology specialist before making any changes to their diet, treatment plan, or lifestyle based on the content herein. Therapies and tests mentioned, including immune or integrative treatments, should always be…
All product names, test references, and therapy mentions are for informational context only and do not constitute endorsement. Results and experiences may vary among individuals.